These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22779333)

  • 21. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Susceptibility to antimicrobial drugs used in the prophylaxis of meningococcal disease: situation after an epidemic wave].
    Arreaza L; de la Fuente L; Fernández S; Vázquez JA
    Rev Esp Quimioter; 2000 Jun; 13(2):182-6. PubMed ID: 10918092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005.
    Can Commun Dis Rep; 2007 Jun; 33(10):1-15. PubMed ID: 17691125
    [No Abstract]   [Full Text] [Related]  

  • 26. [Meningococcal vaccines. Global epidemiological situation and strategies for prevention by vaccination].
    Rivero Calle I; Rodriguez-Tenreiro Sánchez C; Martinón-Torres F
    Enferm Infecc Microbiol Clin; 2015 Apr; 33(4):257-67. PubMed ID: 25795150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New guidelines for management and prevention of meningococcal disease in Australia. Meningococcal Disease Working Party of the National Health and Medical Research Council.
    Patel MS; Collignon PJ; Watson CR; Condon RJ; Doherty RR; Merianos A; Stewart GJ
    Med J Aust; 1997 Jun; 166(11):598-601. PubMed ID: 9201182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Invasive meningococcal infections in the Fribourg canton. Reasons for and development of a vaccination program in Gruyere in February 2001].
    Renevey F; Demierre G; Chuard C; Regamey C
    Rev Med Suisse Romande; 2001 Aug; 121(8):569-72. PubMed ID: 11565217
    [No Abstract]   [Full Text] [Related]  

  • 29. Meningococcal disease and prevention at the Hajj.
    Borrow R
    Travel Med Infect Dis; 2009 Jul; 7(4):219-25. PubMed ID: 19717104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemic.
    Lennon D
    N Z Med J; 2008 Mar; 121(1270):110-2. PubMed ID: 18364765
    [No Abstract]   [Full Text] [Related]  

  • 31. Meningococcal vaccines: a neglected topic in travel medicine?
    Wilder-Smith A
    Expert Rev Vaccines; 2009 Oct; 8(10):1343-50. PubMed ID: 19803757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presenting features of meningococcal disease, public health messages and media publicity: are they consistent?
    Aponso D; Bullen C
    N Z Med J; 2001 Mar; 114(1127):83-5. PubMed ID: 11297142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hepatitis A in Poland in the years 2006-2007].
    Baumann A
    Przegl Epidemiol; 2009; 63(2):241-4. PubMed ID: 19799253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use and misuse of media headlines: lessons from the MeNZB immunisation campaign.
    Turner NM; York DG; Petousis-Harris HA
    N Z Med J; 2009 Mar; 122(1291):22-7. PubMed ID: 19322252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003.
    Can Commun Dis Rep; 2006 Apr; 32(8):97-107. PubMed ID: 16685767
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effectiveness of an immunization campaign with group A and C meningococcal polysaccharide vaccine in controlling an outbreak of group C meningococcal disease].
    Gong J; Li CY; Dong BQ; Huang JZ; Quan Y; Lu WZ; Luo CH; Mao WC; Liao HZ; Fang JS; Cui XL; Xie GL; Wu XH; Lan RW
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):552-5. PubMed ID: 19040035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Invasive meningococcal disease--management and treatment].
    Garlicki A; Bociqga-Jasik M; Kalinowska-Nowak A
    Przegl Epidemiol; 2008; 62 Suppl 1():39-44. PubMed ID: 22320034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
    Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of epidemic group A meningococcal disease in Auckland.
    Lennon D; Gellin B; Hood D; Leach DT; Woods GM; Williams P; Thakur S; Crombie D
    N Z Med J; 1993 Jan; 106(948):3-6. PubMed ID: 8423925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Meningococcal infections in Warsaw's district].
    Dulny G; Grzybowska W; Tyski S
    Przegl Epidemiol; 1998; 52(3):227-35. PubMed ID: 9919916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.